# Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

> **NCT03125694** · PHASE3 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 250 (actual)

## Conditions studied

- Uncontrolled Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin 100mg
- **DRUG:** Pioglitazone 30 mg

## Key facts

- **NCT ID:** NCT03125694
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2017-04-01
- **Final completion:** 2017-04-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125694, "Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03125694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*